Engineered immune cells take on HPV cancers in early trial
NCT ID NCT03578406
First seen Jan 21, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-stage trial tested a new treatment for people with HPV16-positive head and neck or cervical cancer that had spread or come back. The therapy uses a patient's own immune cells, specially trained to recognize and attack HPV-infected cancer cells. Some of these cells were also designed to release a substance that blocks a common cancer defense mechanism. The main goal was to find the safest dose, and only 9 people took part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Qingzhu Jia
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.